Dr. Nadler's preliminary hearing will take place next year between May 1 and May 5 and between May 8 and May 12 after a confirmation hearing on April 24.
The new treatment is indicated for men who have previously received at least one androgen receptor signaling pathway inhibitor and taxane-based chemotherapy.